Clinical trial selection failure

Carrell D. Challenges in adapting existing clinical natural language processing systems to multiple, diverse health care setttings. Cartmell K. Patient participation in cancer clinical trials: a pilot test of lay navigation. Trials Comm. Chang B. Patient recruitment to a randomized clinical behavioral therapy for chronic heart failure. BMC Med.

Chien C. An evolutionary approach to rehabilitation scheduling. A case study. Chin Feman S. Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. Cohen D. Rosiglitazone: what went wrong? Covinsky K. The impact of serious illness on patients' families. Study to understand prognoses and preferences for outcomes and risks of treatment.

Crowther M. Phase 4 research: what happens when the rubber meets the road? ASH Education Book. Cryder C. Informative inducement: study payment as a signal of risk. Csimma C. Large clinical trials in musculoskeletal trauma: are they possible? Lessons learned from the international study of the use of rhBMP-2 in open tibial fractures.

Bone Joint Surg. D'Agostino R. The slippery slope of surrogate outcomes. Trials Cardiovasc. Dansky K. Patient satisfaction with ambulatory healthcare services: waiting time and filling time. Health Serv. Daugherty C. Perceptions of cancer patients and their physicians involved in phase 1 trials. Davis T. Informed consent for clinical trials: a comparative study of standard versus simplified forms.

De Wit N. Participation and successful patient recruitment in primary care. Demner-Fushman D. What can natural language processing do for clinical decision support? Dickson S. Reflecting on the methodological challenges of recruiting to a United Kingdom-wide, multi-centre, randomised controlled trial in gynaecology outpatient settings.

DiMasi J. The cost of drug development. Donovan J. Who can best recruit to randomized trials? Edwards P. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst. El-Sadr W. Financial incentives for linkage to care and viral suppression among HIV-positive patients. Fan W. The power of social media analysis. Feller S. Fletcher B. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. Fouad M. Enrollment of patients with lung and colorectal cancers onto clinical trials.

Getz K. Predicting successful site performance. Characterizing the real cost of site regulatory compliance. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf. Godskesen T. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials.

Hadden K. Halpern S. The continuing unethical conduct of underpowered clinical trials. Heneghan C. Why clinical trial outcomes fail to translate into benefits for patients.

Henon C. Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open. Hill N. Patients with pulmonary arterial hypertension in clinical trials. Who are they? Hjorth M. Physician's attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Cost-effectiveness of methods in personalized medicine.

Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Hripcsak G. Use of natural language processing to translate clinical information from a database of , chest radiographic reports. Hrobjartsson A.

Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Hughes J. What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain.

Hui D. Attrition rates, reasons and predictive factors in supportive and pallative oncology clinical trials. Hurtado-Chong A. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results.

Hwang T. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern. Ibrahim F. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Institute of Medicine. National Academic Press; Washington D. C: Committee on Cancer Clinical Trials. Work Shop Summary. Jalgaonkar S.

An audit of protocol deviations submitted to an institutional ethics committee of a tertiary care hospital. PLoS One. Javid S. A prospective analysis of the influence of older age of physician and patient decision-making when considering enrollment in breast cancer clinical trials.

Jones R. STICH surgical treatment for ischemic heart failure trial enrollment. Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. Keller J. Fundamentals of Computational Intelligence. Krieger J. Linguistic strategies for improving informed consent in clinical trials among low health literacy patient.

La Cour J. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. Larson G. Vitals; March Levett K. Site-specific predictors of successful recruitment to a perinatal clinical trial.

Lievre M. Premature discontinuation of clinical trials for reasons not related to efficacy, safety, or feasibility. Lincoff A. Heart J. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Linde K. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis.

Lopienski K. The statistical analysis of a clinical trial when a protocol amendment changed the inclusion critera. Lovato L. Recruitment for controlled clinical trials: literature summary and annotated bibliography.

Luo H. Quality of inclusion criteria in the registered clinical trials of heart failure with preserved ejection fraction: is it time for a change? Majhail N. Pilot study of patient and caregiver out-of-pocket costs of allogenic hematopoietic cell transplantation.

Bone Marrow Transplant. Make B. How can we assess outcomes of clinical trials: the MCID approach. Martinson B. Effectiveness of monetary incentives for recruiting adolescents to an intervention trial to reduce smoking. Log in to leave a comment. Sign in. Forgot your password? Get help. Privacy Policy.

Create an account. Password recovery. Improving Liver Cancer Diagnosis and Therapy. Are Genetic Mutations Really Random? Abstract There are more than 1 million primary hospitalizations for heart failure HF annually in the USA alone, and post-discharge outcomes remain persistently poor despite available therapies and quality improvement initiatives.

Access to Document Link to publication in Scopus. Link to citation list in Scopus. Fingerprint Dive into the research topics of 'Site selection for heart failure clinical trials in the USA'. Together they form a unique fingerprint. View full fingerprint. Gheorghiade, M. Heart Failure Reviews , 20 4 , Harinstein, Matthew E.

However, one of the most common reasons for failure are design issues. The most important variables for clinical trial design are the selection of the right patient , the right dosing and the right endpoint. The right endpoint matters to ensure that a new drug is of essence and shows the desired effects. When a novel treatment goes to clinical trial, certain characteristics of a good endpoint must be checked.

Secondly, the right dose , such as amount of an intervention , route of administration , interval dosing and the duration of administration play an important role. The most common mistake with dosing is selecting a dose that is too high or too low. The last parameter for a good endpoint is the right patient.